Spearhead Capital Advisors, LLC Editas Medicine, Inc. Transaction History

Spearhead Capital Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 25, 2022	SELL	$26.55 - $40.57 $204,833 - $312,997	-7,715 Closed	0 $0
Q3 2021 Oct 27, 2021	SELL	$39.27 - $72.94 $13,116 - $24,361	-334 Reduced 4.15%	7,715 $317,000
Q2 2021 Aug 10, 2021	SELL	$31.29 - $56.64 $11,796 - $21,353	-377 Reduced 4.47%	8,049 $456,000
Q1 2021 Apr 28, 2021	BUY	$39.71 - $90.58 $15,844 - $36,141	399 Added 4.97%	8,426 $354,000
Q4 2020 Feb 02, 2021	SELL	$27.07 - $84.35 $25,120 - $78,276	-928 Reduced 10.36%	8,027 $563,000
Q2 2020 Jul 16, 2020	BUY	$18.5 - $34.34 $165,667 - $307,514	8,955 New	8,955 $265,000
Q1 2020 Apr 17, 2020	SELL	$14.88 - $32.78 $148,576 - $327,308	-9,985 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$19.49 - $32.63 $194,607 - $325,810	9,985 New	9,985 $296,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Spearhead Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Spearhead Capital Advisors, LLC with notifications on news.